Diagnostic Criteria for Multiple Sclerosis

Core Diagnostic Principle

The diagnosis of MS requires objective evidence of inflammatory-demyelinating injury disseminated in both space and time within the CNS, with no better alternative explanation for the clinical presentation. 1, 2

Diagnostic Algorithm by Clinical Presentation

Two or More Attacks + Two or More Objective Lesions

No additional testing is required for MS diagnosis when attacks are separated by ≥30 days and affect different CNS locations with objective examination findings (optic disc pallor, internuclear ophthalmoplegia, pyramidal signs, sensory level, cerebellar signs, bladder dysfunction). 1, 2
If MRI or CSF are performed and return negative or atypical, extreme caution must be taken before confirming MS—alternative diagnoses must be actively pursued. 1, 2

Two or More Attacks + One Objective Lesion

Dissemination in space (DIS) must be demonstrated through MRI showing lesions in ≥2 of 5 CNS locations: periventricular (≥3 lesions required), cortical/juxtacortical, infratentorial, spinal cord, or optic nerve. 2, 3, 4
Alternative pathway: ≥2 MRI lesions consistent with MS plus positive CSF (oligoclonal IgG bands different from serum OR elevated IgG index >0.7) can substitute for full DIS criteria. 1, 3

One Attack + Two or More Objective Lesions

Dissemination in time (DIT) must be demonstrated through one of three methods: 1, 2
- Simultaneous gadolinium-enhancing and non-enhancing lesions on a single MRI (if scan performed ≥3 months after clinical event)
- New T2 or gadolinium-enhancing lesion on follow-up MRI performed ≥3 months after baseline scan
- A second clinical attack affecting a different CNS site

One Attack + One Objective Lesion (Clinically Isolated Syndrome)

Both DIS and DIT must be demonstrated using the criteria above. 1, 2
This typically requires MRI showing lesions in ≥2 of 5 CNS locations PLUS evidence of new lesion formation on follow-up imaging or a second clinical attack. 2, 3

Insidious Neurological Progression (Primary Progressive MS)

All three of the following are mandatory: 1, 2
1. Abnormal CSF (oligoclonal bands or elevated IgG index)—this is non-negotiable for PPMS diagnosis
2. DIS demonstrated by MRI: ≥9 T2 brain lesions OR ≥2 spinal cord lesions OR 4–8 brain lesions plus 1 spinal cord lesion
3. DIT demonstrated by: continuous clinical progression for ≥1 year OR new MRI lesions on follow-up

MRI Technical Requirements and Interpretation

Essential Sequences and Parameters

Minimum technical standards: 1.5T field strength, ≤3mm slice thickness with no gap, 1×1mm in-plane resolution. 2
Required brain sequences: axial T2-weighted/proton-density (or T2-FLAIR), sagittal T2-FLAIR for corpus callosum evaluation, pre- and post-gadolinium T1-weighted. 2
Spinal cord imaging: whole spine (cervical, thoracic, lumbar) with fat-suppressed sequences when spinal symptoms present or brain MRI equivocal. 2
Optic nerve imaging: fat-suppressed sequences in atypical presentations. 2

Lesion Characteristics That Support MS Diagnosis

Perivenular orientation (central vein sign) is highly specific for MS and useful when conventional findings are ambiguous. 2, 4
Paramagnetic rim lesions indicate chronic active inflammation and help distinguish MS from mimics. 2, 4
Typical distribution: inferior corpus callosum involvement (asymmetric), ovoid periventricular lesions (Dawson's fingers), juxtacortical/cortical lesions. 2

Red Flags Suggesting Non-MS Diagnosis

Lesions in atypical locations not characteristic of MS distribution. 2
Atypical contrast-enhancement patterns (thick, nodular, or ring-enhancing without central vein). 2
Longitudinally extensive spinal cord lesions (≥3 vertebral segments)—suggests NMOSD; check AQP4-IgG antibodies. 3, 5
Absence of brain lesions in patients with isolated spinal presentation—strongly consider NMOSD or MOGAD. 3, 5

CSF Analysis: Indications and Interpretation

When CSF Is Mandatory

Primary progressive MS (cannot be diagnosed without abnormal CSF). 1, 2
MRI does not satisfy DIS or DIT criteria. 2, 3
Atypical clinical presentation. 2, 3
Patients >50 years (to distinguish from vascular white matter disease). 2, 3

Definition of Positive CSF

Oligoclonal IgG bands detected by isoelectric focusing that differ from serum bands (present in >95% of MS patients when optimized methods used). 1, 3
OR elevated IgG index >0.7 (provides 99% positive predictive value for oligoclonal bands). 1, 3
Lymphocytic pleocytosis should be <50 cells/mm³; higher counts suggest alternative pathology. 2, 3

Critical Caveat

Absence of oligoclonal bands strongly argues against MS and should prompt evaluation for alternative demyelinating disorders (NMOSD, MOGAD). 3
Laboratory quality varies markedly—use state-of-the-art isoelectric focusing to avoid false-negative results. 1, 2

2024 McDonald Criteria Updates

Key Additions

Optic nerve lesions now count as a fifth CNS location for DIS. 2, 4, 6
Cortical and juxtacortical lesions are combined into a single category. 2, 4
No distinction between symptomatic and asymptomatic lesions for DIS or DIT assessment. 2, 3
Central vein sign and paramagnetic rim lesions can provide supportive evidence when available. 4, 7
Kappa free-light chains in CSF can be used as supportive evidence in specific situations. 4

Special Population Modifications

Pediatric patients <11 years: require ≥1 T1 hypointense lesion AND ≥1 periventricular lesion to distinguish MS from monophasic demyelination; MOG-antibody testing mandatory. 2, 6
Pediatric patients ≥11 years: apply identical adult DIS/DIT criteria. 2
Patients >50 years or with vascular risk factors: require ≥3 periventricular lesions abutting lateral ventricles to separate MS from age-related white matter changes. 2

Differential Diagnosis and Exclusion Criteria

Mandatory Laboratory Exclusions

AQP4-IgG antibodies (to exclude NMOSD)—especially with longitudinally extensive transverse myelitis or severe optic neuritis. 3, 5
MOG-IgG antibodies (to exclude MOGAD)—especially in pediatric patients <12 years. 6, 5
Antiphospholipid antibodies, lupus serologies (cerebral ischemia/vasculitis in young adults). 1, 2
HTLV-1 serology (endemic regions). 1, 2
Lyme serology (endemic areas). 1, 2
Syphilis serology (meningovascular syphilis). 1, 2

Clinical Red Flags Requiring Broader Differential

Age <10 or >59 years at onset. 1, 2
Progressive onset without relapses. 1, 2
Unusual features: dementia, epilepsy, aphasia, isolated cranial nerve palsies (especially isolated eighth nerve—extremely rare in MS, <1%). 2
Bilateral sudden hearing loss, sudden focal symptoms, gaze-evoked or downbeat nystagmus, concurrent severe bilateral vestibular loss. 2

Diagnostic Outcomes

Multiple Sclerosis: all required criteria fulfilled. 1, 2
Possible Multiple Sclerosis: criteria not completely met but patient remains at risk; close follow-up warranted. 1, 2
Not Multiple Sclerosis: criteria fully explored and not met, or alternative diagnosis identified. 1, 2

Critical Pitfalls to Avoid

Never diagnose MS on MRI alone—clinical evidence of neurologic attacks or progression is mandatory. 2, 3
Never diagnose MS based solely on subjective symptoms—objective examination findings are required. 2
Never diagnose MS if tests are negative or atypical without exhaustive exclusion of mimics. 1, 2
Misinterpreting MRI in patients with few lesions carries high misdiagnosis risk—evaluate both individual lesion characteristics and overall pattern. 2
Detection of MS mimic antibodies (AQP4-IgG, MOG-IgG) does not automatically exclude MS—co-existing conditions can occur, but alternative diagnoses should be favored when they better explain the clinical picture. 2

Diagnosis Without MRI (Resource-Limited Settings)

Clinical-Only Pathway

≥2 attacks + ≥2 objective lesions (different CNS locations, ≥30 days apart) allows definitive MS diagnosis without paraclinical testing. 2
≥2 attacks + 1 objective lesion requires CSF analysis (mandatory) and VEP (strongly recommended). 2
1 attack (any lesions) requires CSF, VEP, and monitoring for second attack. 2
Progressive course requires CSF (mandatory), documented ≥1 year continuous progression, and VEP (optional). 2

Visual Evoked Potentials (VEP)

VEP is the single most valuable paraclinical test when MRI unavailable—demonstrates subclinical optic nerve involvement in 30–50% of MS patients without visual symptoms. 2
Characteristic MS pattern: prolonged P100 latency (>100ms) with preserved waveform morphology. 1, 2

What are the diagnostic criteria for multiple sclerosis?

Help us tailor your experience